Literature DB >> 9540158

Clinical effects of mutations to CD95 (Fas): relevance to autoimmunity?

J P de Villartay1, F Rieux-Laucat, A Fischer, F Le Deist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9540158     DOI： 10.1007/bf00787227

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  55 in total

1.  Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation.

Authors:  M Benkerrou; F Le Deist; J P de Villartay; S Caillat-Zucman; F Rieux-Laucat; N Jabado; M Cavazzana-Calvo; A Fischer
Journal:  Eur J Immunol       Date:  1997-08       Impact factor: 5.532

Review 2.  Contenders in FasL/TNF death signaling.

Authors:  J L Cleveland; J N Ihle
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

3.  Enhanced and accelerated lymphoproliferation in Fas-null mice.

Authors:  M Adachi; S Suematsu; T Suda; D Watanabe; H Fukuyama; J Ogasawara; T Tanaka; N Yoshida; S Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

4.  Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B.

Authors:  S A Marsters; J P Sheridan; C J Donahue; R M Pitti; C L Gray; A D Goddard; K D Bauer; A Ashkenazi
Journal:  Curr Biol       Date:  1996-12-01       Impact factor: 10.834

5.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

6.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

7.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  Transgenic T cell receptor interactions in the lymphoproliferative and autoimmune syndromes of lpr and gld mutant mice.

Authors:  C L Sidman; J D Marshall; H Von Boehmer
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

9.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.

Authors:  P Dowling; G Shang; S Raval; J Menonna; S Cook; W Husar
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307
View more
  1 in total

1.  FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome.

Authors:  Hye Sun Kuehn; Iusta Caminha; Julie E Niemela; V Koneti Rao; Joie Davis; Thomas A Fleisher; João B Oliveira
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.